Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) had its price objective upped by investment analysts at Wells Fargo & Company from $165.00 to $190.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 10.40% from the company’s previous close.

Several other research firms also recently commented on GILD. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. HSBC boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Jefferies Financial Group restated a “buy” rating and issued a $185.00 target price on shares of Gilead Sciences in a report on Friday, October 23rd. TD Cowen reiterated a “buy” rating on shares of Gilead Sciences in a report on Friday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $163.96.

Gilead Sciences Stock Up 3.9%

GILD stock traded up $6.50 during trading on Friday, reaching $172.11. 4,513,284 shares of the stock were exchanged, compared to its average volume of 6,782,397. The firm’s 50 day moving average is $150.33 and its 200 day moving average is $139.55. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $175.65. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market cap of $213.40 billion, a P/E ratio of -64.56 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the prior year, the firm earned $2.47 earnings per share. Gilead Sciences’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, research analysts forecast that Gilead Sciences will post -0.48 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the transaction, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock valued at $15,877,860 in the last ninety days. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Gilead Sciences in the second quarter valued at approximately $15,393,785,000. Legal & General Group Plc bought a new position in Gilead Sciences during the second quarter valued at $1,316,606,000. Deutsche Bank AG purchased a new stake in Gilead Sciences in the second quarter worth $918,387,000. Jupiter Topco LLC purchased a new stake in Gilead Sciences in the second quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Gilead Sciences in the second quarter worth $398,905,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly results exceeded expectations: Gilead reported third-quarter revenue of $8.3 billion, up 6.8% year over year and approximately $500 million above consensus. Non-GAAP EPS of $2.55 also surpassed estimates of roughly $2.17–$2.19. Gilead Sciences Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: 2026 sales outlook was raised: Management now expects full-year product sales of approximately $31.0 billion to $31.3 billion, up from $30.1 billion to $30.4 billion, reflecting strong HIV demand and broader base-business growth. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: Growth beyond Biktarvy was encouraging: Trodelvy sales rose 41.7% year over year to $506 million, while management highlighted strong performance across its HIV portfolio. Gilead also agreed to acquire PepStar’s oral IL-23R inhibitor program for $1.275 billion upfront, supporting its future pipeline. Gilead Sciences Why I Remain Bullish After Q3
• Positive Sentiment: Analyst support improved: Needham raised its price target to $200 and maintained a Buy rating, while Cantor Fitzgerald increased its target to $175 and kept an Overweight rating after the earnings report. Analysts Increase Forecasts on Gilead Sciences
• Neutral Sentiment: Gilead secured a pan-Canadian reimbursement agreement for LYVDELZI, potentially expanding access to the primary biliary cholangitis treatment. The company also declared a quarterly dividend of $0.82 per share.
• Negative Sentiment: Longer-term pricing pressure remains: Management said Medicare pricing changes are expected to reduce Biktarvy’s price by about 38% beginning in 2028, creating an estimated $1.5 billion annual revenue headwind. The company also lowered or widened its 2026 EPS outlook, and some analysts cautioned that third-quarter HIV growth benefited from temporary inventory and channel effects. Gilead Hikes 2026 Sales Outlook
• Negative Sentiment: Gilead agreed to pay $45 million to settle Texas allegations involving unlawful incentives to healthcare providers, adding a legal and compliance expense.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.